Valeritas, Bridgewater, N.J.-based insulin delivery device, closed a $100m structured debt financing with Capital Royalty L.P.
The company intends to use the funds to further support the US commercialization of the V-Go, its insulin delivery device.
Led by Kristine Peterson, Chief Executive Officer, Valeritas makes V-Go, a disposable device for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. The V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes, thereby providing an alternative to taking multiple daily insulin injections.
The company had raised $150m equity financing in 2011 (read here).
FinSMEs
07/06/2013